Switch theme
Sign up to access all valuation multiples
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.
2016
408
LTM Revenue $45.5M
LTM EBITDA -$538M
$0.8M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Vir Biotechnology has a last 12-month revenue (LTM) of $45.5M and a last 12-month EBITDA of -$538M.
In the most recent fiscal year, Vir Biotechnology achieved revenue of $63.7M and an EBITDA of -$538M.
Vir Biotechnology expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Vir Biotechnology valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $45.5M | XXX | $63.7M | XXX | XXX | XXX |
| Gross Profit | $45.0M | XXX | $62.9M | XXX | XXX | XXX |
| Gross Margin | 99% | XXX | 99% | XXX | XXX | XXX |
| EBITDA | -$538M | XXX | -$538M | XXX | XXX | XXX |
| EBITDA Margin | -1182% | XXX | -844% | XXX | XXX | XXX |
| EBIT | -$545M | XXX | -$552M | XXX | XXX | XXX |
| EBIT Margin | -1198% | XXX | -867% | XXX | XXX | XXX |
| Net Profit | -$485M | XXX | -$522M | XXX | XXX | XXX |
| Net Margin | -1066% | XXX | -819% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 2, 2025, Vir Biotechnology's stock price is $5.
Vir Biotechnology has current market cap of $706M, and EV of $0.8M.
See Vir Biotechnology trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $0.8M | $706M | XXX | XXX | XXX | XXX | $-3.52 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 2, 2025, Vir Biotechnology has market cap of $706M and EV of $0.8M.
Vir Biotechnology's trades at 0.0x EV/Revenue multiple, and -0.0x EV/EBITDA.
Equity research analysts estimate Vir Biotechnology's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Vir Biotechnology has a P/E ratio of -1.5x.
See valuation multiples for Vir Biotechnology and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $706M | XXX | $706M | XXX | XXX | XXX |
| EV (current) | $0.8M | XXX | $0.8M | XXX | XXX | XXX |
| EV/Revenue | 0.0x | XXX | 0.0x | XXX | XXX | XXX |
| EV/EBITDA | -0.0x | XXX | -0.0x | XXX | XXX | XXX |
| EV/EBIT | -0.0x | XXX | -0.0x | XXX | XXX | XXX |
| EV/Gross Profit | 0.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.5x | XXX | -1.4x | XXX | XXX | XXX |
| EV/FCF | -0.0x | XXX | -0.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialVir Biotechnology's last 12 month revenue growth is -63%
Vir Biotechnology's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $1.5M for the same period.
Vir Biotechnology's rule of 40 is -1747% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Vir Biotechnology's rule of X is -1340% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Vir Biotechnology and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -63% | XXX | -49% | XXX | XXX | XXX |
| EBITDA Margin | -1182% | XXX | -844% | XXX | XXX | XXX |
| EBITDA Growth | -5% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -1747% | XXX | -907% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -1340% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 795% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 965% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Vir Biotechnology acquired XXX companies to date.
Last acquisition by Vir Biotechnology was XXXXXXXX, XXXXX XXXXX XXXXXX . Vir Biotechnology acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Vir Biotechnology founded? | Vir Biotechnology was founded in 2016. |
| Where is Vir Biotechnology headquartered? | Vir Biotechnology is headquartered in United States of America. |
| How many employees does Vir Biotechnology have? | As of today, Vir Biotechnology has 408 employees. |
| Who is the CEO of Vir Biotechnology? | Vir Biotechnology's CEO is Dr. Marianne De Backer, M.B.A.,M.Sc.,PhD. |
| Is Vir Biotechnology publicy listed? | Yes, Vir Biotechnology is a public company listed on NAS. |
| What is the stock symbol of Vir Biotechnology? | Vir Biotechnology trades under VIR ticker. |
| When did Vir Biotechnology go public? | Vir Biotechnology went public in 2019. |
| Who are competitors of Vir Biotechnology? | Similar companies to Vir Biotechnology include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Vir Biotechnology? | Vir Biotechnology's current market cap is $706M |
| What is the current revenue of Vir Biotechnology? | Vir Biotechnology's last 12 months revenue is $45.5M. |
| What is the current revenue growth of Vir Biotechnology? | Vir Biotechnology revenue growth (NTM/LTM) is -63%. |
| What is the current EV/Revenue multiple of Vir Biotechnology? | Current revenue multiple of Vir Biotechnology is 0.0x. |
| Is Vir Biotechnology profitable? | Yes, Vir Biotechnology is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Vir Biotechnology? | Vir Biotechnology's last 12 months EBITDA is -$538M. |
| What is Vir Biotechnology's EBITDA margin? | Vir Biotechnology's last 12 months EBITDA margin is -1182%. |
| What is the current EV/EBITDA multiple of Vir Biotechnology? | Current EBITDA multiple of Vir Biotechnology is -0.0x. |
| What is the current FCF of Vir Biotechnology? | Vir Biotechnology's last 12 months FCF is -$379M. |
| What is Vir Biotechnology's FCF margin? | Vir Biotechnology's last 12 months FCF margin is -834%. |
| What is the current EV/FCF multiple of Vir Biotechnology? | Current FCF multiple of Vir Biotechnology is -0.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
